芪苈强心胶囊联合 ACEI/ARB 药物治疗慢性心力衰竭的系统性评价

目的:系统评价芪苈强心胶囊联合 ACEI/ARB 药物治疗慢性心力衰竭的疗效;方法:计算机检索中国知网(CNKI)、维普(VIP)、万方(Wanfang)、Pubmed、Cochrane library 等数据库自建库至 2020 年 3 月 27 日有关芪苈强心胶囊联合 ACEI/ARB 药物治疗慢性心力衰竭(CHF)的临床随机试验文献。由 2 位评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用 RevMan 5.3 软件进行 Meta 分析。结果:共纳入 8 篇文献,文献评价质量较低,共有 792 例 CHF 患者,其中观察组 397 例,对照组 395 例。Meta 结果分析显示:观察组的 6 分钟步行试验(6MTW)MD=54.78,95%Cl(36.68,72.88),P<0.00001]、左心室射血分数(LVEF)MD=4.96,95%Cl(1.96,7.97),P=0.001]、左心室舒张末期内径(LVEDD)MD=-4.58,95%CI(-5.97,-3.19),P<0.00001]、总有效率MD=3.37,95%CI(1.98,5.74)P<0.00001]显著优于对照组,差异有统计学意义。而在 BNP 方面,对照组与观察组无统计学意义MD=-137.49,95%Cl(-290.92,15.94),P=0.05]。结论:芪苈强心胶囊联合 ACEI/ARB 类药物对 CHF 患者的临床疗效显著。

Systematic Evaluation of Qili Qiangxin Capsule Combined with ACEI / ARB Drugs in the Treatment of Chronic Heart Failure

Objective:To systematically evaluate the efficacy of Qiliqiangxin Capsule combined with ACEI/ARB drugs in the treatment of chronic heart failure;Method:Computer search of databases such as CNKI,VIP,Wanfang,Pubmed,Cochrane library,etc.Since the establishment of the database until March 27,2020,the clinical randomized trial literature of Qiliqiangxin Capsules combined with ACEI/ARB drugs in the treatment of chronic heart failure (CHF).After two reviewers independently screened the literature,extracted data,and evaluated the risk of bias in the included studies,the RevMan 5.3 software was used for meta-analysis.Results:A total of 8 articles were included,and the quality of the literature evaluation was low.There were a total of 792 CHF patients,including 397 cases in the observation group and 395 cases in the control group.Meta analysis showed that:the observation group’s 6-minute walk test (6MTW)MD=54.78,95%Cl (36.68,72.88),P<0.00001],left ventricular ejection fraction (LVEF)MD=4.96,95%Cl (1.96,7.97),P=0.001],left ventricular end diastolic diameter (LVEDD)MD=-4.58,95%CI (-5.97,-3.19),P<0.00001],total effective rateMD=3.37,95 %CI (1.98,5.74) P<0.00001]was significantly better than the control group,and the difference was statistically significant.In terms of BNP,there was no statistical significance between the control group and the observation groupMD=-137.49,95% Cl (-290.92,15.94),P=0.05].Conclusion:Qiliqiangxin Capsule combined with ACEI/ARB drugs has a significant clinical effect on CHF patients.